Veteran Drug Developer Joins Turn Biotechnologies to Lead Pre-clinical Development Efforts
Turn Biotechnologies welcomes Hans Hofland, PhD, to a new role leading the development of regenerative medicine therapies in dermatology, immunology, and ophthalmology, as well as program management.
Dr. Hofland, who will serve as SVP of Pre-Clinical Development, has worked with more than a dozen leading dermatology and Immunology companies.
He most recently worked at Evommune, a clinical-stage biotechnology company he co-founded and served as senior vice president of research.
Evommune – which develops novel therapies to treat immune-mediated chronic inflammatory diseases – raised more than $150 million and progressed its assets to the clinic.
Previously, Dr. Hofland headed Research and Nonclinical Development at Dermira, where he worked for more than seven years until the company’s acquisition by Eli Lilly. He earlier held the position of senior director of GlaxoSmithKline’s Center for Skin Biology, a position he also held under Stiefel Laboratories prior to its acquisition by GlaxoSmithKline. Additionally, he has worked with Connetics, Aventis, Somatix Therapy Corporation, and OPTIME Therapeutics, and has consulted with several other leading biotechnology companies.
During his productive career, Dr. Hofland has been involved with 13 INDs and helped bring 10 different products to market. He holds 21 granted and pending patents and has written more than 25 scientific journal articles.
Dr. Hofland received his doctorate in Pharmaceutical Sciences from the University of Leiden in the Netherlands.
Co-founder and Head of Research Vittorio Sebastiano will continue to lead the company’s Discovery Research efforts to advance ERA™ and explore new mechanisms for the company.
Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level and developing transformative drug delivery systems.
ABOUT TURN BIOTECHNOLOGIES
Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level and developing transformative drug delivery systems. The company’s proprietary mRNA-based ERA™ reprogramming technology restores optimal gene expression by combatting the effects of aging in the epigenome. This restores cells’ ability to prevent or treat disease and heal or regenerate tissue. It will help to fight incurable chronic diseases. Its eTurna™ delivery platform uses unique formulations to precisely deliver cargo to specific organs, tissues, and cell types.
The company is completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, and developing therapies for ophthalmology, osteo-arthritis, and the muscular system. For more information, see www.turn.bio.
FOR MORE INFORMATION, CONTACT:
Jim Martinez, rightstorygroup